Medications & Treatments

Featured

Think scale! Engaging Private Pharmacies to Improve Public Health 

A version of this story first appeared on IDSA’s Science Speaks platform By Emily Delmotte Lisinopril 20 mg by mouth at 8am? Check. After verifying the Read More

Why smart government spending matters for the SDG medicines target

The World Health Organization’s first global report on diabetes  highlights the disease’s “alarming surge” with rates that have quadrupled in fewer than three decades. The report reminds us Read More

Reflections on a year of malnutrition

Malnutrition is frustrating. I often sit in the office, analyzing data from our programs, and feel helpless. Children who stay the same height for two Read More

Latest

HIV and Hormonal Contraception: Bench and Bedside

No abstract available


Think scale! Engaging Private Pharmacies to Improve Public Health 

A version of this story first appeared on IDSA’s Science Speaks platform By Emily Delmotte Lisinopril 20 mg by mouth at 8am? Check. After verifying the Read More


Innovation is at the heart of Seattle

One of the great public health intervention programs of modern times was conceived by two Seattle visionaries, a doctor at the University of Washington (UW) and a Seattle Fire Department chief, both of whom asked a simple question: “Could behavior change at the fire department change the mortality of the city?” Today, we know the […] ; ; ; ;Related StoriesOur 8 favorite photos of 2016PATH: 40 years of innovation and impactIn Davos, Rx for epidemics: tech partnerships ;


Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

by Andreas H. Laustsen, Kristoffer H.


Does Increased Medication Use among Seniors Increase Risk of Hospitalization and Emergency…

Objective To examine the extent of the health risks of consuming multiple medications among the older population.


@MSF Video: Patents and the fight for #generics

Intellectual property protects those items that we can’t live without – think Netflix and the iPhone 7 – and those that we would surely die without, including life saving and extending medications.  Today’s video covers the latter and the barriers much of the developed world faces courtesy of patent laws that protect pharmaceutical companies.  This issue has come to recent attention as the UN’s Panel on Access to Medicines published its recommendations to Big Pharma’s chagrin. At the crux of the UN Recommendations is a struggle that pits profits against people.  Enacted in 1995 by the World Trade Organization, the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) introduced minimum standards for protecting intellectual property, including patents on medicine.  TRIPS proved a boon for international trade, but set a 20-year patent on novel medication.  Only after the patent lapses can generic alternatives hit the marketplace.  It is at this point when many lifesaving and extending drugs are first available to the developing world.  The price tag of a medication to treat HIV/AIDS can drop from $10,000 per year to $200 due to generics. Under TRIPS, each country has the right to a grant compulsory license, as stated in this excerpt: Where the law of a Member allows for other use of the subject matter of a patent without the authorization of the right holder, including use by the government or third parties authorized by the government, the following provisions shall be respected: (b)   such use may only be permitted if, prior to such use, the proposed user has made efforts to obtain authorization from the right holder on reasonable commercial terms and conditions and that such efforts have not been successful within a reasonable period of time. This requirement may be waived by a Member in the case of national emergency or other circumstances of extreme urgency or in cases of public non-commercial use. In situations of national emergency or other circumstances of extreme urgency, the right holder shall, nevertheless, be notified as soon as reasonably practicable.


Effect of package insert language on health-care providers’ perceptions of…

Despite national and international recommendations that support influenza immunisation in pregnant women, global adoption of these programmes is inadequate.1 Reviews by public health experts of inactivated influenza vaccines have not identified safety concerns in pregnant women or their offspring.2 These reviews were based largely on non-product-specific data and observational studies because data from product-specific, randomised controlled trials in pregnant women are scarce. However, clinical trial data are the basis for the language of the vaccine product information and package inserts approved by regulatory authorities regarding indications, safety, and use in specific populations.


U.N.’s medicines report a victory for Doctors Without Borders, a blow to pharma industry

The highly anticipated report on access to medicines was released by the U.N. today. Still hot off the presses, the report has garnered both admiration and scorn. The biopharmaceutical industry called the document a “missed opportunity” by ignoring the common issues that restrict access. For Doctors Without Borders, it was a major victory


Growing antibiotic resistance forces updates to recommended treatment for sexually transmitted…

New guidelines for the treatment of 3 common sexually transmitted infections (STIs) were today issued by WHO in response to the growing threat of antibiotic resistance.


Morals, morale and motivations in data fabrication: Medical research fieldworkers views and…

Publication date: October 2016 Source:Social Science & Medicine, Volume 166 Author(s): Patricia Kingori, René Gerrets Data fabrication, incorrect collection strategies and poor data management, are considered detrimental to high-quality scientific research.


Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics…

C-reactive protein point-of-care testing reduced antibiotic use for non-severe acute respiratory tract infection without compromising patients’ recovery in primary health care in Vietnam. Health-care providers might have become familiar with the clinical picture of low C-reactive protein, leading to reduction in antibiotic prescribing in both groups, but this would have led to a reduction in observed effect, rather than overestimation. Qualitative analysis is needed to address differences in context in order to implement this strategy to improve rational antibiotic use for patients with acute respiratory infection in low-income and middle-income countries.


Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of…

by Sanne Terryn, Aurélie Francart, Heidi Rommelaere, Catelijne Stortelers, Steven Van Gucht Post-exposure prophylaxis (PEP) against rabies infection consists of a combination of passive immunisation with plasma-derived human or equine immune globulins and active immunisation with vaccine delivered shortly after exposure. Since anti-rabies immune globulins are expensive and scarce, there is a need for cheaper alternatives that can be produced more consistently.


AIDS 2016: How Seattle scientists’ frustration turns to hope in hunt for an HIV vaccine

Editors note: As part of our coverage of the 21st International AIDS Conference, we are reposting part two of a series from the Seattle Times about the Fred Hutchinson Cancer Research Center’s effort to find an effective HIV vaccine. View the full report here. By Nina Shapiro, Seattle Times staff reporter CAPE TOWN, South Africa


AIDS 2016: Plenary talk proposes $90, $90, $90 as cost of HIV and viral hepatitis drugs

Categories: AIDS2016DURBAN, South Africa – Today’s plenary session today saw a new 90-90-90 goal set in a talk on tuberculosis and viral hepatitis today: $90 for HIV treatment, $90 for hepatitis B treatment and $90 for hepatitis C cure. Dr.Anton Pozniak, the director of HIV services at Chelsea and Westminster Hospital NHS Trust in London, issued the challenge. The hepatitis […](Read more…)


Older Posts »